Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic alpha-synuclein oligomers in Parkinson's disease - Aix-Marseille Université Access content directly
Journal Articles Glycoconjugate Journal Year : 2021

Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic alpha-synuclein oligomers in Parkinson's disease

Abstract

Current therapeutic strategies are centered on the dopaminergic system, with limited efficacy, so that a treatment that has a direct impact on the underlying disease pathogenesis is urgently needed.-synuclein is a privileged target for such therapies, this protein has been in the past wrongly considered as exclusively intracellular, so that the impact of paracrine neurotoxicity mechanisms in PD have been largely ignored. In this article we review the data showing that lipid rafts act as plasma membrane machineries for the formation of-synuclein pore-like oligomers which trigger an increase of intracellular Ca 2+. This Ca 2+ influx is responsible for a self-sustained cascade of neurotoxic events, including mitochondrial oxidative stress, tau phosphorylation, Ca 2+ release from the
Fichier principal
Vignette du fichier
Yahi et al Parkinson 2021.pdf (2.53 Mo) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03600650 , version 1 (07-03-2022)

Identifiers

  • HAL Id : hal-03600650 , version 1

Cite

Nouara Yahi, Coralie Scala, Henri Chahinian, Jacques Fantini. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic alpha-synuclein oligomers in Parkinson's disease. Glycoconjugate Journal, 2021. ⟨hal-03600650⟩
10 View
44 Download

Share

Gmail Mastodon Facebook X LinkedIn More